Global Discovery Chemistry, Janssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75A, 45007 Toledo, Spain.
Neuroscience Discovery, Janssen Pharmaceutica NV, a Johnson and Johnson Company, Turnhoutseweg 30, 2340 Beerse, Belgium.
J Med Chem. 2024 Sep 12;67(17):15569-15585. doi: 10.1021/acs.jmedchem.4c01227. Epub 2024 Aug 29.
Allosteric modulators of the metabotropic group II receptors, mGluR and mGluR, have been widely explored due to their ability to modulate cognitive and neurological functions in mood disorders, although none have been approved yet. In our search for new and selective mGluR negative allosteric modulators (NAMs), series of 6,7-dihydropyrazolo[1,5-]pyrazin-4(5)-one derivatives were identified from our published series of 1,3,5-trisubstituted pyrazoles. SAR evolution of the initial hit resulted in 100-fold improvement in the mGluR NAM potency and subsequent selection of compound based on its overall profile, including selectivity and ADMET properties. Further pharmacokinetic-pharmacodynamic (PK-PD) relationship built showed that compound occupied the mGluR receptor in a dose-dependent manner. Additionally, the compound revealed activity in V-maze as a model of cognition from a dose of 0.32 mg/kg. Compound was selected to be evaluated further.
由于代谢型谷氨酸受体 2(mGluR2)调节剂能够调节情绪障碍中的认知和神经功能,因此广泛探索了 mGluR 和 mGluR 的变构调节剂(NAM),尽管目前尚无此类调节剂获得批准。在寻找新型、选择性 mGluR 负变构调节剂(NAM)的过程中,我们从已发表的 1,3,5-三取代吡唑系列中鉴定出了一系列 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物。对初始命中化合物进行 SAR 进化,使 mGluR NAM 效力提高了 100 倍,随后根据化合物的整体特性(包括选择性和 ADMET 特性)选择了化合物 。进一步建立的药代动力学-药效学(PK-PD)关系表明,化合物 以剂量依赖性方式占据 mGluR 受体。此外,该化合物在 V 迷宫中显示出认知活性,其剂量为 0.32mg/kg。选择化合物 进一步评估。